Discover the Smith lab’s new approach to treating Fragile X syndrome using Saracatinib, originally a cancer drug. Learn how this $100,000 FRAXA research grant-funded study opens up hopeful avenues.
Read more
FRAXA Research Foundation – Finding a Cure for Fragile X Syndrome
Accelerating Fragile X Research for Effective Treatments